You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Nikita Wright -- 3026 2022-08-16 18:53:13 |
2 format Jason Zhu -1 word(s) 3025 2022-08-25 08:26:49 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Jinna, N.;  Rida, P.;  Smart, M.;  Labarge, M.;  Jovanovic-Talisman, T.;  Natarajan, R.;  Seewaldt, V. Therapeutic Resistance of Hypoxia in Triple-Negative Breast Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/26214 (accessed on 21 December 2025).
Jinna N,  Rida P,  Smart M,  Labarge M,  Jovanovic-Talisman T,  Natarajan R, et al. Therapeutic Resistance of Hypoxia in Triple-Negative Breast Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/26214. Accessed December 21, 2025.
Jinna, Nikita, Padmashree Rida, Max Smart, Mark Labarge, Tijana Jovanovic-Talisman, Rama Natarajan, Victoria Seewaldt. "Therapeutic Resistance of Hypoxia in Triple-Negative Breast Cancer" Encyclopedia, https://encyclopedia.pub/entry/26214 (accessed December 21, 2025).
Jinna, N.,  Rida, P.,  Smart, M.,  Labarge, M.,  Jovanovic-Talisman, T.,  Natarajan, R., & Seewaldt, V. (2022, August 16). Therapeutic Resistance of Hypoxia in Triple-Negative Breast Cancer. In Encyclopedia. https://encyclopedia.pub/entry/26214
Jinna, Nikita, et al. "Therapeutic Resistance of Hypoxia in Triple-Negative Breast Cancer." Encyclopedia. Web. 16 August, 2022.
Therapeutic Resistance of Hypoxia in Triple-Negative Breast Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms23168844

Triple-negative breast cancer (TNBC) surpasses other breast cancer (BC) subtypes as the most challenging to treat due to its lack of traditional BC biomarkers. Nearly 30% of TNBC patients express the androgen receptor (AR), and the blockade of androgen production and AR signaling have been the cornerstones of therapies for AR-positive TNBC. However, the majority of women are resistant to AR-targeted therapy, which is a major impediment to improving outcomes for the AR-positive TNBC subpopulation. The hypoxia signaling cascade is frequently activated in the tumor microenvironment in response to low oxygen levels; activation of the hypoxia signaling cascade allows tumors to survive despite hypoxia-mediated interference with cellular metabolism. The activation of hypoxia signaling networks in TNBC promotes resistance to most anticancer drugs including AR inhibitors. The activation of hypoxia network signaling occurs more frequently in TNBC compared to other BC subtypes. 

hypoxia hypoxia-inducible factors adaptation

1. Introduction

Triple-negative breast cancer (TNBC) continues to be the most difficult-to-treat BC subtype. TNBCs do not express the conventional BC targets currently exploited for therapeutic intervention, including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1]. TNBCs are inherently more aggressive, with an increased risk of death within 5 years post-diagnosis and a higher rate of distant metastasis and recurrence following surgery compared to other breast cancer subtypes [2][3]. Precision medicine approaches to targeting TNBC are complicated by inter- and intra-tumoral heterogeneity.
Over the past few decades, the androgen receptor (AR) has been highlighted as an alternate endocrine target of interest for the subset of TNBC patients positive for AR expression. AR expression is assessed by immunohistochemistry (IHC); about 20%–40% of TNBC tumors express AR [4]. AR is most highly expressed in the “luminal AR (LAR)” molecular subtype of TNBC; however, in vitro and in vivo experiments involving AR-inhibitors and AR knockdown have demonstrated that non-LAR molecular subtypes of TNBC may also be critically dependent on AR protein for viability, proliferation, migration, and invasion [5]. These results led to the notion that AR-targeted therapies could exploit this AR dependence and benefit multiple molecular subtypes of AR-positive TNBC. Although several AR inhibitors (such as bicalutamide, abiraterone acetate, and enzalutamide) have elicited significant antitumor activity in advanced clinical trials with AR-positive TNBC patients, approximately only one in five experienced sustained clinical benefit. This limited success suggests the development of therapeutic resistance among the majority of patients [4][5][6][7][8]. However, the mechanisms of resistance to AR inhibition in TNBC remain underexplored. Moving the needle on understanding of this resistance to AR-targeted therapies is imperative for improving therapeutic efficacy and for the advancement of AR inhibitory drugs to the FDA-approval stage.
Hypoxia, or limited oxygen availability due to insufficient blood supply, is a unique feature of most solid tumors [9]. Rapid and uncontrolled tumor growth can lead to tumors outgrowing their surrounding vasculature, which leads to a significant drop in normal oxygen levels (from 9%–2%) and the development of hypoxia (<2%). Oxygen is necessary for tumor cell metabolism and proliferation. Thus, slow-dividing cells located in hypoxic areas of tumors can escape most anticancer agents that kill rapidly dividing cells [10]. Furthermore, hypoxia induces profound gene expression changes that promote tumor cells’ survival, the growth of new vasculature, energy metabolism, lineage plasticity, and heterogeneity, often conferring an aggressive and metastatic phenotype [11][12]. Thus, hypoxia has been significantly implicated in therapeutic resistance to multiple anticancer agents and underlies poor patient prognosis [13][14][15].
The adaptive response to hypoxia is regulated by hypoxia-inducible factors (HIFs), which modulate hypoxic gene expression and regulate oxygen homeostasis. Heterodimeric HIF is composed of an oxygen-labile α subunit and a stable β subunit; HIF α/β heterodimers are thus comprised of one of three α subunits (HIF-1α, HIF-2α, or HIF-3α) and one of two β subunits (HIF-β and aryl hydrocarbon receptor nuclear translocator or ARNT). The HIF-α subunit undergoes proteasomal degradation under normoxic conditions; in contrast, HIF-β and ARNT are constitutively expressed and reside in the nucleus. Under hypoxic conditions, stabilized HIF-α translocates to the nucleus, where the active HIF-α/ARNT or HIF-α/HIF-β complex activates the transcription of a large group of target genes after binding to cognate hypoxia-responsive elements (HREs) [16][17][18].

2. Tried and Tested: Androgen Synthesis and AR Signaling as Therapeutic Targets for TNBC

Since AR-driven/-dependent TNBC is a potentially actionable subtype, androgen- and AR-targeting therapies have been explored for their ability to stymie disease progression in AR-positive TNBC [19]. Clinical trials involving TNBC patients with both early-stage and advanced disease have evaluated the clinical benefit rates (CBRs) for patients under treatment with anti-androgen drugs, including bicalutamide or enzalutamide, which were administered as single agents as well as in combination therapies. Drugs that reduce androgen production are also being evaluated for AR-positive TNBC and have shown varying degrees of efficacy but were largely supportive of targeting the androgen/AR axis in AR-positive TNBC.
Bicalutamide is FDA-approved for the treatment of advanced PC in combination with a luteinizing hormone-releasing hormone analog. Bicalutamide is orally available and is a competitive inhibitor of AR that permits AR nuclear localization and binding to chromatin but preferentially recruits AR corepressors rather than coactivators [20]. A clinical study conducted by investigators at the Memorial Sloan Kettering Cancer Center (NCT00468715/TBCRC011) showed that daily treatment with 150 mg bicalutamide led to 19% CBR lasting longer than 6 months and a median progression-free survival (PFS) of 12 weeks in ER-negative/PR-negative/AR-positive metastatic BC patients [6]. These proof-of-concept data in AR-positive BC provided an impetus to pursue next-generation AR antagonists because bicalutamide can have partial agonist effects [21]. PC patients who develop resistance to bicalutamide are oftentimes responsive to the next-generation antagonist enzalutamide, which (a) has an eightfold higher affinity for AR than bicalutamide and (b) is a robust inhibitor of AR signaling that blocks AR nuclear translocation and coactivator interactions and attenuates the DNA binding capacity of AR [22].
In a phase I dose-escalation study in patients with metastatic BC in 2013, enzalutamide was well tolerated at 160 mg daily. In a 2015 phase II study, among the AR-positive patients evaluable for response, the CBR (defined as complete response + partial response + stable disease) at 16 weeks was 42% with patients receiving 160 mg enzalutamide daily. About 34% of the participants in the study continued to show clinical benefits after 24 weeks. Furthermore, when a novel, binary, gene signature-based predictive biomarker that was reflective of AR signaling was used to stratify patients, the outcomes for diagnostic-positive patients were more favorable in all response measures, including CBR16 (39% vs 11%), CBR24 (36% vs 6%), and median PFS (16.1 weeks vs 8.1 weeks), when compared with those of patients who tested negative for this companion diagnostic. Interestingly, this companion diagnostic was a stronger predictor of response to enzalutamide than AR expression (evaluated by IHC) alone. These responses to an AR antagonist supported (a) the development of anti-AR therapy for the treatment of a subgroup of patients with TNBC [8], (b) the development of companion diagnostics that better identify the androgen/AR-dependence of tumors, and (c) the pre-planned incorporation of such predictive biomarkers (that are superior to AR positivity alone) and novel biomarker discovery into clinical trials. The ENDEAR trial, which was scheduled to be an international, double-blind, randomized, placebo-controlled, three-arm phase III study in TNBC patients who tested positive for the companion diagnostic developed during the phase II trial previously mentioned, was unfortunately abandoned in 2017 based on a joint decision by the partnering pharmaceutical companies, citing a need to improve the clarity on the role of androgen signaling in BC. Based on the promising data available regarding the metastatic setting, a phase II study is currently evaluating the feasibility of enzalutamide as endocrine therapy in the adjuvant setting (1 year of enzalutamide 160 mg orally daily) for patients with early-stage (Stages I–III) TNBC of the LAR subtype (NCT02750358). This single-arm trial has met its primary endpoint of feasibility; however, the median overall survival (OS) has not yet been reached. Apalutamide and darolutamide are two promising new-generation AR inhibitors under evaluation in phase III clinical trials in patients with non-metastatic CRPC (NCT01946204 and NCT02200614, respectively). Apalutamide, structurally similar to enzalutamide, has exhibited a similar success rate as enzalutamide at a lower dosage in an LNCaP xenograft mouse model but does not induce AR nuclear translocation or DNA binding [23]. Darolutamide is particularly interesting owing to its ability to also antagonize the AR mutants F876 L, W741 L, and T877A [24]. The applicability and efficacy of these drugs in the context of AR-positive TNBC are yet to be extensively studied.
Agents that target steroidogenic enzymes to impair intracrine and adrenal androgen biosynthesis and concomitantly reduce downstream estrogen synthesis have also been tested in clinical trials for TNBC; abiraterone acetate, a CYP17 inhibitor, is one such therapeutic, which is a robust, orally available, selective inhibitor of both 17α-hydroxylase and C17, 20-lyase. In a phase II multicenter trial that aimed to assess the safety and efficacy of abiraterone acetate in combination with prednisone (which has to be included to offset the increase in aldosterone production that results from reduced cortisol levels) in women with metastatic or inoperable locally advanced AR-positive TNBC, the CBR at 6 months was 20.0% and median PFS was 2.8 months. This suggested that some TNBC patients with molecular apocrine-like tumors may benefit from the coadministration of abiraterone acetate and prednisone. Seviteronel, an oral, selective CYP17-lyase inhibitor and AR antagonist, is also currently being evaluated as a novel option for the treatment of AR-positive TNBC because this agent does not cause a decrease in cortisol and no steroid supplementation is required. Preliminary pharmacokinetic data from a large phase I/II trial for seviteronel in AR-positive TNBC and ER-positive metastatic BC suggested that the bioavailability of seviteronel may be sex-specific [25]. The phase II trial in this population established the promising CYP17-lyase inhibitory activity of seviteronel, as evidenced by an early and potent reduction in both estradiol and testosterone [26]. Pre-clinical data also advocate for the administration of seviteronel as a radiotherapy-sensitizing agent in AR-positive TNBC [27].
Since other oncogenic aberrations may co-exist with AR dependency, combination regimens involving AR inhibitors and other targeted therapies are also underway for AR-positive TNBC. Palbociclib, an orally administered and highly selective and reversible CDK4/6 inhibitor, prevents the onset of the S phase, resulting in cytotoxicity and growth arrest. Studies have shown that luminal phenotypes, elevated cyclin D1 and Rb protein expression, and reduced p16 expression are all associated with sensitivity to Palbociclib [28]. AR-positive TNBC often exhibits a luminal gene expression profile and has intact Rb protein; these observations provide a rationale for combining AR inhibitors with Palbociclib for the treatment of AR-positive TNBC. A phase I/II trial (NCT02605486) in patients with metastatic BC [26] met its pre-specified endpoint of PFS of at least 6 months. A trial testing the combination of bicalutamide and ribociclib (another CDK4/6 inhibitor) is also underway (NCT03090165). AR antagonists have also been paired with drugs that target the PI3K/AKT/mTOR pathways because AR-positive BCs are often associated with activating PIK3CA mutations and pAKT [29][30][31]. Pre-clinical studies showed that LAR cell lines are significantly more sensitive to NVP-BEZ235 (a dual PI3 K/mTOR inhibitor) when compared to cell lines of basal-like TNBC molecular subtypes [31]. These findings catalyzed an investigator-initiated, multi-institutional phase I/II study (TBCRC032) that evaluated the safety and efficacy of enzalutamide alone or in combination with the PI3K inhibitor, taselisib, in patients with metastatic AR-positive (≥10%) BC [32]. The combination of enzalutamide and taselisib significantly increased the CBR in the AR-positive TNBC patients. Importantly, analyses confirmed earlier findings that AR protein expression alone is insufficient for identifying patients with AR-dependent tumors, and a greater understanding of TNBC molecular subtypes and AR splice variants may identify patients more or less likely to respond to AR antagonists. Since the LAR subtype is generally resistant to conventional multidrug neoadjuvant chemotherapy (NAC) regimens and exhibits low rates of pathologic complete response, or pCR [33], a phase II clinical trial was carried out to assess whether combining AR inhibition with NAC would improve pCR or near-pCR in early-stage AR-positive (10%) TNBC patients treated with enzalutamide and weekly paclitaxel (NCT02689427). The results of this trial showed that 33.3% of TNBC patients who did not respond to conventional NAC showed a pCR with the enzalutamide and paclitaxel combination; notably, all responders showed an upregulated androgen response pathway as measured by transcriptomic analysis in pre-treatment biopsies [34].

3. The Arch Nemesis: Hypoxia as a Barrier in Androgen/AR Signaling Inhibition in Cancer

A significant body of evidence shows that tumor hypoxia interferes with therapies that disrupt AR signaling or reduce androgen levels in PC. A recent study showed that enzalutamide induces hypoxia and microenvironment adaptation and that two cytokines—interleukin-8 (IL8) and vascular endothelial growth factor A (VEGF-A)—upregulated by this treatment-induced hypoxia may contribute to this treatment resistance [35]. This also showed that the concurrent inhibition of both IL8 and VEGF-A in PC pre-clinical models prolonged tumor sensitivity to enzalutamide. One primary mechanism of this hypoxia-mediated resistance to AR-targeted therapies is via upregulating AR signaling. Several studies have shown that overexpressing HIF-1α in PC cells stimulated AR signaling with the androgen dihydrotestosterone (DHT), enhanced AR transcriptional activity, and subsequently increased secretion of VEGF [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43]. Specifically, hypoxia increased AR translocation to the nucleus and recruitment to the prostate-specific antigen (PSA) promoter [36][44]. It was also shown via chromatin immunoprecipitation that HIF-1α interacts with AR on the human PSA gene promoter in DHT-stimulated PC cells, suggesting that HIF-1α and AR may be cooperating to activate AR target genes [45]. Collectively, these findings suggest that hypoxia enhances the AR signal transduction pathway. As a result, hypoxia has been reported to drive insensitivity to androgen/AR-targeted therapies in PC. In PC cells, DHT-mediated AR signaling induced HIF-1α expression, and the dual treatment of enzalutamide and HIF-1α inhibition abrogated cell growth, induced apoptosis, and reduced VEGF levels more effectively than the administration of each treatment alone [39]. These studies thus provide a strong impetus for combining therapeutic targeting of the HIF-1α and AR pathways as a strategy to combat enzalutamide resistance.
It was also discovered that HIF-1α coordinates AR translocation to the nucleus via binding to β-catenin and AR to form a ternary complex that binds to the androgen response elements [46]. Under hypoxic conditions, the dietary polyphenol, resveratrol, reduced HIF-1α levels and inhibited β-catenin nuclear accumulation to suppress hypoxia-induced AR transactivation in prostate tumors possibly in a proteasome-independent manner [40]. These findings suggest that targeting the Wnt/β-catenin signaling axis in combination with androgen/AR signaling may also circumvent hypoxia-mediated resistance to AR-targeted therapies. Furthermore, the AR-signaling-mediated induction of HIF-1 was shown to occur via the phosphatidylinositol 3-kinase (PI3K) signaling as the inhibition of this pathway blocked HIF-1 activation [43]. Lastly, it was recently shown that hypoxia simultaneously upregulates HIF-1α and transient receptor potential melastatin subfamily member 7 (TRPM7) in androgen-independent PC cells and that knockdown of TRPM7 inhibited hypoxia-induced migration and invasion via the increased RACK1-mediated degradation of HIF-1α [47].
Some groups have begun to unravel other mechanisms of intra-tumoral hypoxia-mediated resistance to androgen/AR signaling inhibition. Hypoxia-mediated resistance to the potent second-generation AR inhibitor, enzalutamide, was shown to mechanistically occur in PC via restoration of glucose-6-phosphate isomerase (GPI), which is transcriptionally repressed by AR in hypoxia and maintains glucose metabolism and energy homeostasis under hypoxic conditions [37]. AR inhibition restores GPI, which was shown to promote resistance to this inhibition via redirecting glucose flux from the androgen/AR-dependent pentose phosphate pathway to the hypoxia-induced glycolysis pathway. Thus, GPI inhibition was shown to circumvent enzalutamide resistance in vivo. Cancer stem cells have also been implicated in treatment resistance to AR-targeted therapies in PC [48][49]. ADT has been shown to increase cancer stem cell numbers in prostate tumors and HIF signaling in response to hypoxia and induce the expression of stemness and EMT genes that promote the emergence of these cancer stem cells [50][51][52]. Furthermore, HIF-1α was shown to regulate CD44, which is expressed on stem-like BC cells, by increasing the presence of CD44 molecules and the percentage of CD44 positive cells under hypoxic conditions [53]. Thus, the expansion of the cancer stem cell subpopulation upon the induction of adaptive HIF signaling may also be conferring resistance to AR-targeted therapies.

4. Double Trouble: Hypoxia in Triple-Negative Breast Cancer

Hypoxic regions have been observed in over 50% of breast tumors but more frequently in TNBC. Genomic profiling revealed high HIF-1α signaling activity in basal-like/TNBCs [54]. Specifically, HIF-1α expression was observed to be highly upregulated in TNBCs to withstand a hypoxic tumor microenvironment. TNBCs have also been shown to upregulate bicarbonate transporters (NDBTs) such as SLCA4 and SLC4A5, which regulate tumor pH levels when adapting to hypoxic conditions [55].
The enhanced hypoxic signaling observed in TNBC has been suggested to underlie advanced progression and treatment resistance in TNBC, which may also be undermining the efficacy of AR inhibition. Specifically, HIF-1α upregulates Snail expression, which increases the migration and invasiveness of BC cells by downregulating E-cadherin. Farnesyltransferase treatment of TNBC cells to inhibit HIF-1α expression decreased mRNA levels of HIF-1α pathway genes such as Snail, glucose transporter 1, pyruvate dehydrogenase kinase 1, and lactate dehydrogenase A [56]. HIF-1α and HIF-2α silencing in TNBC xenografts significantly reduced tumor growth [57]. In TNBC, HIF-1α upregulated complement 1 q binding protein (C1QBP), which blocked metastasis of TNBC cells and increased their sensitivity to paclitaxel [58]. The depletion of C1QBP in TNBC cells also decreased VCAM-1 expression and suppressed the activation of hypoxia-induced protein kinase C-nuclear factor-κappa B signaling [58]. The nano-treatment of TNBC in vitro and in vivo with the hypoxia-targeting drug tirapazamine, effectively abrogated tumor cell growth and progression in hypoxic regions [41]. The inhibition of TNBC hypoxia-induced NDBTs was shown to notably suppress migration and invasion in vitro and in vivo via attenuating the NDBT-mediated hypoxic phospho-signaling activation and modulating the expression of critical EMT-related genes, such as vimentin, which prevents downregulation of E-cadherin [55]. The inhibition of the hypoxia-induced carbonic anhydrase IX in TNBC cell lines impaired their ability to form new vasculature and mammospheres as well as metastasize [59]. Hence, targeting hypoxia in TNBC has been shown to increase tumor sensitivity to chemotherapies such as cisplatin, doxorubicin, and 5-fluorouracil [60][61][62][63].
Hypoxia has also been shown to predict prognosis in TNBC. Positive HIF-1α IHC expression significantly correlated with greater tumor size, higher histological grade, positive lymph node status, and higher tumor TNM stage as well as poorer postoperative survival [64]. The enrichment of a hypoxia-related three-gene signature model was shown to predict poorer overall survival (OS) in TNBC patients [65]. Furthermore, a high combined hypoxia and immune-base gene signature score predicted a poorer prognosis among TNBC patients [66].

References

  1. Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; et al. American Society of Clinical O, College of American P: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013, 31, 3997–4013.
  2. Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13, 4429–4434.
  3. Lin, N.U.; Claus, E.; Sohl, J.; Razzak, A.R.; Arnaout, A.; Winer, E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 2008, 113, 2638–2645.
  4. Grellety, T. Androgen receptor-positive triple negative breast cancer: From biology to therapy. Bull. Cancer 2020, 107, 506–516.
  5. Barton, V.N.; D’Amato, N.C.; Gordon, M.A.; Lind, H.T.; Spoelstra, N.S.; Babbs, B.L.; Heinz, R.E.; Elias, A.; Jedlicka, P.; Jacobsen, B.M.; et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol. Cancer Ther. 2015, 14, 769–778.
  6. Gucalp, A.; Tolaney, S.; Isakoff, S.J.; Ingle, J.N.; Liu, M.C.; Carey, L.A.; Blackwell, K.; Rugo, H.; Nabell, L.; Forero, A.; et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin. Cancer Res. 2013, 19, 5505–5512.
  7. Bonnefoi, H.; Grellety, T.; Tredan, O.; Saghatchian, M.; Dalenc, F.; Mailliez, A.; L’Haridon, T.; Cottu, P.; Abadie-Lacourtoisie, S.; You, B.; et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann. Oncol. 2016, 27, 812–818.
  8. Traina, T.A.; Miller, K.; Yardley, D.A.; Eakle, J.; Schwartzberg, L.S.; O’Shaughnessy, J.; Gradishar, W.; Schmid, P.; Winer, E.; Kelly, C.; et al. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J. Clin. Oncol. 2018, 36, 884–890.
  9. Shao, C.; Yang, F.; Miao, S.; Liu, W.; Wang, C.; Shu, Y.; Shen, H. Role of hypoxia-induced exosomes in tumor biology. Mol. Cancer 2018, 17, 120.
  10. Birner, P.; Schindl, M.; Obermair, A.; Plank, C.; Breitenecker, G.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000, 60, 4693–4696.
  11. Wigerup, C.; Pahlman, S.; Bexell, D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol. Ther. 2016, 164, 152–169.
  12. Chen, A.; Sceneay, J.; Godde, N.; Kinwel, T.; Ham, S.; Thompson, E.W.; Humbert, P.O.; Moller, A. Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene 2018, 37, 4214–4225.
  13. Wilson, W.R.; Hay, M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11, 393–410.
  14. Ueda, S.; Saeki, T.; Osaki, A.; Yamane, T.; Kuji, I. Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis. Clin. Cancer Res. 2017, 23, 5769–5778.
  15. Jing, X.; Yang, F.; Shao, C.; Wei, K.; Xie, M.; Shen, H.; Shu, Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 2019, 18, 157.
  16. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732.
  17. Boddy, J.L.; Fox, S.B.; Han, C.; Campo, L.; Turley, H.; Kanga, S.; Malone, P.R.; Harris, A.L. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 2005, 11, 7658–7663.
  18. Wang, G.L.; Semenza, G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 1993, 90, 4304–4308.
  19. McNamara, K.M.; Yoda, T.; Takagi, K.; Miki, Y.; Suzuki, T.; Sasano, H. Androgen receptor in triple negative breast cancer. J. Steroid Biochem. Mol. Biol. 2013, 133, 66–76.
  20. Osguthorpe, D.J.; Hagler, A.T. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 2011, 50, 4105–4113.
  21. Kemppainen, J.A.; Wilson, E.M. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology 1996, 48, 157–163.
  22. Scher, H.I.; Fizazi, K.; Saad, F.; Taplin, M.E.; Sternberg, C.N.; Miller, K.; de Wit, R.; Mulders, P.; Chi, K.N.; Shore, N.D.; et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012, 367, 1187–1197.
  23. Clegg, N.J.; Wongvipat, J.; Joseph, J.D.; Tran, C.; Ouk, S.; Dilhas, A.; Chen, Y.; Grillot, K.; Bischoff, E.D.; Cai, L.; et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res. 2012, 72, 1494–1503.
  24. Fizazi, K.; Albiges, L.; Loriot, Y.; Massard, C. ODM-201: A new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 2015, 15, 1007–1017.
  25. Bardia, A.; Iafrate, J.A.; Sundaresan, T.; Younger, J.; Nardi, V. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist 2016, 21, 1035–1040.
  26. Gucalp, A.; Traina, T.A. Targeting the androgen receptor in triple-negative breast cancer. Curr. Probl. Cancer 2016, 40, 141–150.
  27. Michmerhuizen, A.R.; Chandler, B.; Olsen, E.; Wilder-Romans, K.; Moubadder, L.; Liu, M.; Pesch, A.M.; Zhang, A.; Ritter, C.; Ward, S.T.; et al. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Front. Endocrinol. 2020, 11, 35.
  28. Finn, R.S.; Dering, J.; Conklin, D.; Kalous, O.; Cohen, D.J.; Desai, A.J.; Ginther, C.; Atefi, M.; Chen, I.; Fowst, C.; et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11, R77.
  29. Doane, A.S.; Danso, M.; Lal, P.; Donaton, M.; Zhang, L.; Hudis, C.; Gerald, W.L. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25, 3994–4008.
  30. Aleskandarany, M.A.; Rakha, E.A.; Ahmed, M.A.; Powe, D.G.; Ellis, I.O.; Green, A.R. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res. Treat. 2011, 127, 407–416.
  31. Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011, 121, 2750–2767.
  32. Lehmann, B.D.; Abramson, V.G.; Sanders, M.E.; Mayer, E.L.; Haddad, T.C.; Nanda, R.; Van Poznak, C.; Storniolo, A.M.; Nangia, J.R.; Gonzalez-Ericsson, P.I.; et al. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR(+) Metastatic Triple-Negative Breast Cancer. Clin. Cancer Res. 2020, 26, 2111–2123.
  33. Lehmann, B.D.; Colaprico, A.; Silva, T.C.; Chen, J.; An, H.; Ban, Y.; Huang, H.; Wang, L.; James, J.L.; Balko, J.M.; et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat. Commun. 2021, 12, 6276.
  34. Lim, S.C.; Jansson, P.J.; Assinder, S.J.; Maleki, S.; Richardson, D.R.; Kovacevic, Z. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. FASEB J. 2020, 34, 11511–11528.
  35. Maxwell, P.J.; McKechnie, M.; Armstrong, C.W.; Manley, J.M.; Ong, C.W.; Worthington, J.; Mills, I.G.; Longley, D.B.; Quigley, J.P.; Zoubeidi, A.; et al. Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers. Mol. Cancer Res. 2022, 20, 841–853.
  36. Park, S.Y.; Kim, Y.J.; Gao, A.C.; Mohler, J.L.; Onate, S.A.; Hidalgo, A.A.; Ip, C.; Park, E.M.; Yoon, S.Y.; Park, Y.M. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res. 2006, 66, 5121–5129.
  37. Geng, H.; Xue, C.; Mendonca, J.; Sun, X.X.; Liu, Q.; Reardon, P.N.; Chen, Y.; Qian, K.; Hua, V.; Chen, A.; et al. Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. Nat. Commun. 2018, 9, 4972.
  38. Yamasaki, M.; Nomura, T.; Sato, F.; Mimata, H. Chronic hypoxia induces androgen-independent and invasive behavior in LNCaP human prostate cancer cells. Urol. Oncol. 2013, 31, 1124–1131.
  39. Fernandez, E.V.; Reece, K.M.; Ley, A.M.; Troutman, S.M.; Sissung, T.M.; Price, D.K.; Chau, C.H.; Figg, W.D. Dual targeting of the androgen receptor and hypoxia-inducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells. Mol. Pharmacol. 2015, 87, 1006–1012.
  40. Mitani, T.; Harada, N.; Tanimori, S.; Nakano, Y.; Inui, H.; Yamaji, R. Resveratrol inhibits hypoxia-inducible factor-1alpha-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. J. Nutr. Sci. Vitaminol. 2014, 60, 276–282.
  41. Chou, Y.T.; Lin, C.Y.; Wen, J.W.; Hung, L.C.; Chang, Y.F.; Yang, C.M.; Wu, L.C.; Ho, J.A. Targeting triple-negative breast cancer with an aptamer-functionalized nanoformulation: A synergistic treatment that combines photodynamic and bioreductive therapies. J. Nanobiotechnol. 2021, 19, 89.
  42. Park, C.; Kim, Y.; Shim, M.; Lee, Y. Hypoxia enhances ligand-occupied androgen receptor activity. Biochem. Biophys. Res. Commun. 2012, 418, 319–323.
  43. Mabjeesh, N.J.; Willard, M.T.; Frederickson, C.E.; Zhong, H.; Simons, J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3’-kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 2003, 9, 2416–2425.
  44. Mitani, T.; Yamaji, R.; Higashimura, Y.; Harada, N.; Nakano, Y.; Inui, H. Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1alpha in a low androgen environment. J. Steroid Biochem. Mol. Biol. 2011, 123, 58–64.
  45. Horii, K.; Suzuki, Y.; Kondo, Y.; Akimoto, M.; Nishimura, T.; Yamabe, Y.; Sakaue, M.; Sano, T.; Kitagawa, T.; Himeno, S.; et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol. Cancer Res. 2007, 5, 383–391.
  46. Mitani, T.; Harada, N.; Nakano, Y.; Inui, H.; Yamaji, R. Coordinated action of hypoxia-inducible factor-1alpha and beta-catenin in androgen receptor signaling. J. Biol. Chem. 2012, 287, 33594–33606.
  47. Yang, F.; Cai, J.; Zhan, H.; Situ, J.; Li, W.; Mao, Y.; Luo, Y. Suppression of TRPM7 Inhibited Hypoxia-Induced Migration and Invasion of Androgen-Independent Prostate Cancer Cells by Enhancing RACK1-Mediated Degradation of HIF-1alpha. Oxid. Med. Cell. Longev. 2020, 2020, 6724810.
  48. Shang, Z.; Cai, Q.; Zhang, M.; Zhu, S.; Ma, Y.; Sun, L.; Jiang, N.; Tian, J.; Niu, X.; Chen, J.; et al. A switch from CD44(+) cell to EMT cell drives the metastasis of prostate cancer. Oncotarget 2015, 6, 1202–1216.
  49. Klarmann, G.J.; Hurt, E.M.; Mathews, L.A.; Zhang, X.; Duhagon, M.A.; Mistree, T.; Thomas, S.B.; Farrar, W.L. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 2009, 26, 433–446.
  50. Cheloni, G.; Tanturli, M.; Tusa, I.; Ho DeSouza, N.; Shan, Y.; Gozzini, A.; Mazurier, F.; Rovida, E.; Li, S.; Dello Sbarba, P. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood 2017, 130, 655–665.
  51. Ma, Y.; Liang, D.; Liu, J.; Axcrona, K.; Kvalheim, G.; Stokke, T.; Nesland, J.M.; Suo, Z. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS ONE 2011, 6, e29170.
  52. Marhold, M.; Tomasich, E.; El-Gazzar, A.; Heller, G.; Spittler, A.; Horvat, R.; Krainer, M.; Horak, P. HIF1alpha Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. Mol. Cancer Res. 2015, 13, 556–564.
  53. Krishnamachary, B.; Penet, M.F.; Nimmagadda, S.; Mironchik, Y.; Raman, V.; Solaiyappan, M.; Semenza, G.L.; Pomper, M.G.; Bhujwalla, Z.M. Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS ONE 2012, 7, e44078.
  54. The Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70.
  55. Carroll, C.P.; Bolland, H.; Vancauwenberghe, E.; Collier, P.; Ritchie, A.A.; Clarke, P.A.; Grabowska, A.M.; Harris, A.L.; McIntyre, A. Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis. Neoplasia 2022, 25, 41–52.
  56. Tanaka, T.; Ikegami, Y.; Nakazawa, H.; Kuriyama, N.; Oki, M.; Hanai, J.; Sukhatme, V.P.; Kaneki, M. Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1alpha and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. J. Cell. Physiol. 2017, 232, 192–201.
  57. Bharti, S.K.; Mironchik, Y.; Wildes, F.; Penet, M.F.; Goggins, E.; Krishnamachary, B.; Bhujwalla, Z.M. Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 2018, 9, 15326–15339.
  58. Wu, H.; Chu, Y.; Sun, S.; Li, G.; Xu, S.; Zhang, X.; Jiang, Y.; Gao, S.; Wang, Q.; Zhang, J.; et al. Hypoxia-Mediated Complement 1q Binding Protein Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates the PKC-NF-kappaB-VCAM-1 Signaling Pathway. Front. Cell Dev. Biol. 2021, 9, 607142.
  59. Sarnella, A.; D’Avino, G.; Hill, B.S.; Alterio, V.; Winum, J.Y.; Supuran, C.T.; De Simone, G.; Zannetti, A. A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity. Int. J. Mol. Sci. 2020, 21, 8405.
  60. Cheng, F.Y.; Chan, C.H.; Wang, B.J.; Yeh, Y.L.; Wang, Y.J.; Chiu, H.W. The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer. Cancers 2021, 13, 606.
  61. Godet, I.; Mamo, M.; Thurnheer, A.; Rosen, D.M.; Gilkes, D.M. Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC. Cancers 2021, 13, 5509.
  62. Sulaiman, A.; McGarry, S.; Chambers, J.; Al-Kadi, E.; Phan, A.; Li, L.; Mediratta, K.; Dimitroulakos, J.; Addison, C.; Li, X.; et al. Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 5788.
  63. Saatci, O.; Kaymak, A.; Raza, U.; Ersan, P.G.; Akbulut, O.; Banister, C.E.; Sikirzhytski, V.; Tokat, U.M.; Aykut, G.; Ansari, S.A.; et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat. Commun. 2020, 11, 2416.
  64. Cui, J.; Jiang, H. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1alpha and c-myc. Medicine 2019, 98, e17370.
  65. Sun, X.; Luo, H.; Han, C.; Zhang, Y.; Yan, C. Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer. Front. Oncol. 2021, 11, 700062.
  66. Yang, X.; Weng, X.; Yang, Y.; Zhang, M.; Xiu, Y.; Peng, W.; Liao, X.; Xu, M.; Sun, Y.; Liu, X. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Aging 2021, 13, 19486–19509.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, Research & Experimental
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Nikita Jinna , Padmashree Rida ,
Max Smart
, Mark LaBarge , Tijana Jovanovic-Talisman , Rama Natarajan , Victoria Seewaldt
View Times: 482
Revisions: 2 times (View History)
Update Date: 25 Aug 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback